UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults
Launched by NATIONAL HEART CENTRE SINGAPORE · Nov 18, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults" is studying why some young adults (under 60 years old) experience heart attacks, even when they don’t have common risk factors like high blood pressure or diabetes. Researchers are using advanced technologies to look closely at genes and other biological factors to find out what might lead to these heart attacks. This study aims to discover new ways to prevent heart disease and improve treatments for those affected.
To join the trial, participants need to be at least 21 years old and either under 50 years old or between 51 and 60 years old with only a couple of risk factors (excluding diabetes) at the time of their heart attack. Participants must be willing to provide consent and attend study visits. Those who are of Chinese, Malay, or Indian descent are eligible, but certain medical conditions and pregnancy may exclude others. If you join the study, you will help researchers learn more about heart disease in young adults, which could lead to better prevention and treatment strategies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult \>21 years old.
- • 2. Age ≤50 years old irrespective of the presence of CV risk factors\* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor\* at the time of myocardial infarction, excluding diabetes mellitus
- • 3. Able to provide informed consent.
- • 4. Patients who are willing and able to comply with the study visit and procedures.
- • 5. Prior type 1 myocardial infarction with angiographically/CT documented significant stenosis of ≥50% in LM or ≥70% in major epicardial/branch vessel (e.g. LAD, LCX, RCA).
- • 6. Patients who are from the three main races (Chinese, Malay, Indian). Race is self-identified by patient.
- • Hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoker
- Exclusion Criteria:
- • 1. Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.
- • 2. Prior PAD and Stroke
- • 3. Female patients who are pregnant
- • 4. Patients who are non-Asian
About National Heart Centre Singapore
The National Heart Centre Singapore (NHCS) is a leading institution dedicated to advancing cardiovascular care and research in Singapore and the Asia-Pacific region. As a premier clinical trial sponsor, NHCS is committed to improving heart health through innovative research and clinical excellence. The center specializes in a wide range of cardiovascular conditions, leveraging cutting-edge technology and a multidisciplinary approach to develop and evaluate new therapies. With a strong emphasis on patient-centered care, NHCS collaborates with various stakeholders to enhance clinical outcomes and contribute to the global body of cardiovascular knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Jonathan Yap
Principal Investigator
National Heart Centre Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported